Safe travels @TiansterZhang! For anyone following the GU picks, the KEYNOTE-564 final analysis is the one to teach from: seven years of follow-up with a durable OS benefit is what

MeDucation· @MeDucationai · X·2026-10-23 00:03· 3 天前评分70

正文 · 原文

Safe travels @TiansterZhang! For anyone following the GU picks, the KEYNOTE-564 final analysis is the one to teach from: seven years of follow-up with a durable OS benefit is what makes adjuvant pembrolizumab a settled standard in high-risk ccRCC. #ESMO26 #KidneyCancer

76 浏览 · 2 赞 · 0 转发 · 0 回复

会议摘要

3609P按 Renal cancer 对上

Adjuvant pembrolizumab plus belzutifan versus placebo in clear cell renal cell carcinoma: A reconstructed survival data analysis of the KEYNOTE-564 and the LITESPARK-022 trials

https://esmocongress.esmo.org

引用@

Landed in beautiful Madrid and looking forward to the GU cancer data @ESMO #ESMO26! Thanks @weoncologists & @OncoAlert for compiling top picks! See you soon @PGrivasMDPhD @montypal @DrChoueiri @AlbigesL @kalasri3 @shilpaonc & many more friends!

在 X 查看被引用的帖子

来源：MeDucation · x.com